Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Class A Common Stock, par value $0.01 per share
-
Shares outstanding
-
4,080,222
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
68,620
-
Shares change
-
+68,020
-
Total reported value, excl. options
-
$788,715
-
Value change
-
+$781,835
-
Number of buys
-
13
-
Number of sells
-
-1
-
Price
-
$11.50
Significant Holders of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) as of Q4 2023
14 filings reported holding VTVT - vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share as of Q4 2023.
vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68,620 shares
of 4,080,222 outstanding shares and own 1.7% of the company stock.
Largest 10 shareholders include Samsara BioCapital, LLC (40,888 shares), VANGUARD GROUP INC (23,519 shares), BlackRock Inc. (1,341 shares), Tower Research Capital LLC (TRC) (1,070 shares), MORGAN STANLEY (840 shares), ROYAL BANK OF CANADA (558 shares), Focused Wealth Management, Inc (250 shares), OSAIC HOLDINGS, INC. (50 shares), Parallel Advisors, LLC (38 shares), and WELLS FARGO & COMPANY/MN (30 shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.